Packing paper and drug packaging rolls

Abstract

Provided is packaging paper which comprises a first resin layer comprising a resin composition containing at least two biodegradable resins and a second resin layer comprising moisture-proof cellophane, in which the ratio of a biodegradable component contained in the entire packaging paper is 90% by mass or more. Also provided is a roll for medicine packaging use, which is provided with strip-like packaging paper and a core tube, in which the packaging paper is wound in a roll-like shape around the core tube, and in which the packaging paper is provided with the first resin layer and the second resin layer comprising moisture-proof cellophane, and the ratio of a biodegradable component contained in the entire packaging paper is 90% by mass or more.

Description

[Technical field]

[0001] The present invention relates to a biodegradable packaging paper and a medicine packaging roll using the packaging paper. This application claims priority to Japanese Application No. 2021-196483 filed on December 2, 2021, and incorporates all of the contents of said Japanese application by reference. [Background technology]

[0002] To prevent patients from forgetting to take their medicine or taking the wrong medicine, medication is dispensed in single doses using individual packaging paper. Conventionally, cellopoly paper, which is a laminate of cellophane and polyethylene film, glassine paper, and the like have often been used as the above-mentioned packaging paper (Patent Document 1). [Prior art documents] [Patent documents]

[0003] [Patent Document 1] JP 2000-335501 A Summary of the Invention [Problem to be solved by the invention]

[0004] In light of the recent increase in efforts toward the SDGs (Sustainable Development Goals), we investigated a new environmentally friendly packaging paper made from biodegradable resin. Specifically, we investigated a packaging paper in which the polyethylene film of cellopoly paper was replaced with a biodegradable resin film, but even when the polyethylene film of cellopoly paper was replaced with a biodegradable resin film, we were unable to provide a packaging paper that satisfied the required performance.

[0005] Packaging paper is an item that requires a barrier against moisture because it is necessary to protect the packaged medicine from atmospheric moisture, etc. On the other hand, biodegradable resins are generally prone to absorbing moisture because they are decomposed mainly by hydrolysis reactions using microbial enzymes. Therefore, biodegradable resins are generally materials having properties that are contrary to the characteristics required for packaging paper, making it difficult to provide biodegradable packaging paper. [Means for solving the problem]

[0006] Under these circumstances, the present inventors conducted extensive research and completed a packaging paper that is biodegradable while satisfying the required properties of packaging paper.

[0007] (1) The packaging paper of the present invention is A first resin layer made of a resin composition containing at least two types of biodegradable resins; A second resin layer made of moisture-proof cellophane; Equipped with The proportion of biodegradable components contained in the entire packaging paper is 90% by mass or more.

[0008] The packaging paper of the present invention is biodegradable while also ensuring moisture resistance to protect the medicine. In addition, the packaging paper contains two types of biodegradable resins, thereby ensuring the flexibility and transparency required of the packaging paper.

[0009] (2) The wrapping paper of (1) above preferably contains, as the biodegradable resin, a polyester-based copolymer using a diol and a dicarboxylic acid as monomer components, and a polylactic acid-based resin. (3) In the wrapping paper of (2) above, the polyester copolymer is preferably polybutylene succinate. In the above cases (2) and (3), the packaging paper has good transparency and flexibility, making it easy for medical staff and patients to handle.

[0010] (4) Furthermore, the content of the polyester-based copolymer in the wrapping paper of (2) or (3) above is preferably less than 50 mass % based on the total amount of the polyester-based copolymer and the polylactic acid-based resin. In this case, the formability during production of the packaging paper is good, making it easier to produce packaging paper with uniform thickness and mechanical properties.

[0011] (5) A medicine packaging roll according to the present invention is a medicine packaging roll including a band-shaped packaging paper and a core tube, the packaging paper being wound around the core tube in a roll shape, The packaging paper is a medicine packaging roll as described in any one of (1) to (4) above. (6) In the medicine packaging roll of (5) above, the strip-shaped packaging paper is folded in half along the longitudinal direction and wound around the core tube. The medicine packaging rolls (5) and (6) above are suitable for use in a medicine packaging device. Effect of the Invention

[0012] The packaging paper of the present invention ensures the transparency and flexibility required of packaging paper, and in addition, is biodegradable and has the moisture resistance required to protect the packaged medicine. The medicine packaging roll of the present invention can be attached to a known medicine packaging device for use. [Brief description of the drawings]

[0013] [Figure 1] FIG. 1 is a perspective view showing an example of a medicine packaging roll according to an embodiment of the present invention. [Figure 2A] FIG. 1 is a perspective view of a packaging paper according to an embodiment of the present invention; [Figure 2B] FIG. 2B is a perspective view showing the packaging paper of FIG. 2A folded in half; [Figure 2C] 2B is a cross-sectional view showing a part of a cross section perpendicular to the longitudinal direction of the packaging paper of FIG. 2A. [Diagram 3]FIG. 2 is a diagram illustrating the process of packaging medicines into individual doses using a packaging paper according to an embodiment of the present invention. [Figure 4] 1 is a front perspective view showing the appearance of an example of a medicine packaging device; [Diagram 5] 5 is a perspective view of a packaging unit included in the medicine dispensing and packaging device shown in FIG. 4, as viewed from above on a side surface. [Figure 6] 1 is a cross-sectional view showing a core tube of a medicine packaging roll including packaging paper according to an embodiment of the present invention. [Figure 7A] 5 is a perspective view showing an internal configuration of a roll support section included in the medicine packaging device shown in FIG. [Figure 7B] 5 is a perspective view showing an internal configuration of a roll support section included in the medicine packaging device shown in FIG. [Figure 8] 5 is an explanatory diagram showing the configuration of a paper remaining amount determination unit in a controller provided in the medicine packaging device shown in FIG. 4. [Figure 9A] FIG. 1 is an explanatory diagram showing a state in which medicines are packaged in a packaging paper according to an embodiment of the present invention; [Figure 9B] FIG. 9B is a partially enlarged view of FIG. 9A. [Figure 10] 1A to 1C are diagrams illustrating a method of manufacturing a packaging paper according to an embodiment of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] Hereinafter, a packaging paper according to an embodiment of the present invention will be described with reference to the drawings. (First embodiment) The packaging paper according to this embodiment is attached to a medicine packaging device when used. In this case, the packaging paper is provided as a medicine packaging roll (also called roll packaging paper). FIG. 1 is a perspective view showing a medicine packaging roll according to an embodiment of the present invention. Fig. 2A is a perspective view of a packaging paper according to an embodiment of the present invention. Fig. 2B is a perspective view showing the packaging paper of Fig. 2A folded in half. Fig. 2C is a cross-sectional view showing a part of a cross section perpendicular to the longitudinal direction of the packaging paper of Fig. 2A.

[0015] As shown in Fig. 1, medicine packaging roll 10 includes strip-shaped packaging paper 11 and a core tube 12. Packaging paper 11 is wound around core tube 12 in a roll shape. The core tube 12 is a tubular member having a through hole 13 that passes through the center in the axial direction.

[0016] Packaging paper 11 is a long, thin, strip-shaped member. Packaging paper 11 is folded in half along the longitudinal direction so as to have an open edge 11a and a crease 11b extending in the longitudinal direction. Packaging paper 11, folded in half, is wrapped around the outer periphery of core tube 12 (see FIGS. 1, 2A, and 2B). 2C, the packaging paper 11 is a laminate including a first resin layer 111 and a second resin layer 112. The structure of the packaging paper 11 will be described in detail later.

[0017] The medicine packaging roll 10 is attached to a medicine packaging device when in use. The packaging paper 11 packages the medicine M in one dose (one packet). FIG. 3 is a schematic diagram showing a process of packaging medicines into single doses (hereinafter also referred to as a packaging process) in the medicine packaging device.

[0018] In the medicine packaging device, a strip-shaped packing paper 11 folded in half is fed from a medicine packaging roll 10, and first, the printing unit 69 prints necessary information on the packing paper 11. Then, the packing paper 11 folded in half is conveyed to the unfolding guide 65 via a guide roller 71 and the like, and is spread out into a V-shape by the unfolding guide 65. Next, a single dose of medicine M is introduced into the packing paper 11 with the open edge 11a spread out from a nozzle portion 67a of a hopper that functions as an inlet for introducing medicine M, and then the packing paper 11 reaches the heat sealing unit 68. The packing paper 11 that has reached the heat sealing unit 68 is sealed by a heat roller 70. In the heat sealing unit 68, a horizontal seal 102 that seals (thermally fuses) the open edge 11a of the packing paper 11 folded in half in the longitudinal direction, and a vertical seal 103 that seals from the open edge 11a to the fold 11b across the packing paper 11 in the lateral direction are formed. In this manner, the medicine packaging device performs a process of packaging the medicine M in single doses with the packaging paper 11 (packaging process).

[0019] The above-mentioned packaging step can be carried out, for example, by using a medicine packaging device 1 shown in Figs. Fig. 4 is a perspective view showing the external appearance of the medicine packing device, Fig. 5 is a perspective view showing a packaging unit provided in the medicine packing device of Fig. 4, as viewed from above on the side. The medicine packaging device 1 includes a tablet supply unit 2, a powdered medicine supply unit 3, a packaging unit 4, and a medicine recovery section 5. The tablet supply unit 2 and the powdered medicine supply unit 3 are provided on the upper side of a housing 6. The packaging unit 4 is disposed in a storage chamber in the housing 6. The medicine recovery section 5 is provided at the front lower part of the medicine packaging device 1. Packaged medicines packaged by the packaging unit 4 are discharged to the medicine recovery section 5. The front opening of the housing 6 is covered with a single-door type cover 8 that can be opened and closed, except for the medicine recovery section 5. When this cover 8 is opened, an operator can access the packaging unit 4 in the storage chamber. The form of the cover 8 is not limited to a single-door type, and may be other forms such as a double-door type.

[0020] A control panel 9 is provided on the upper surface of the housing 6. The operations of the tablet supplying unit 2, the powdered medicine supplying unit 3, and the packaging unit 4 are each controlled based on prescription data input from the control panel 9. In order to control the operation of each unit, the medicine packaging device 1 is provided with a controller 18 consisting of a microcomputer.

[0021] The tablet supplying unit 2 includes a plurality of tablet storage chambers 21 arranged in a matrix. The tablet supplying unit 2 is configured to automatically supply one packet of tablets supplied to each tablet storage chamber 21 to a hopper 67 (see FIG. 5) provided in the packaging unit 4. The tablet supply unit 2 includes a closing cover 25 that covers the rearmost row of the tablet storage cells 21, and a protective cover 26 that covers the entire upper surfaces of the tablet storage cells 21. When the closing cover 25 is closed, the number of tablet storage cells 21 to be used can be changed. When the protective cover 26 is closed, the intrusion of dust, dirt, etc. into the tablet storage cells 21 can be prevented.

[0022] The powdered medicine supplying unit 3 is provided with a long and narrow box (V box 31) having an approximately V-shaped open cross section on the upper surface of the housing 6. The powdered medicine supplying unit 3 is configured to automatically divide the powdered medicine supplied to the V box 31 into individual packets and sequentially supply them to a hopper 67 of the packaging unit 4. Moreover, the powdered medicine supply unit 3 is provided with a movable partition plate 32 in the V-shaped chamber 31 for adjusting the number of portions into which the powdered medicine is divided.

[0023] As shown in FIG. 5, the packaging unit 4 includes a sheet supplying section 63, an unfolding guide 65, a hopper 67, a heat sealing section 68, and a printing section 69. The sheet supplying section 63 unfolds and supplies the packing paper 11 from the medicine packing roll 10 in which the packing paper 11, which has been folded in half along the longitudinal direction in advance, is wound around a core tube 12. The unfolding guide 65 unfolds the packing paper 11 supplied by the sheet supplying section 63, and opens the open edge 11a of the packing paper 11. The hopper 67 receives the medicine M supplied from the tablet supplying unit 2 and the powdered medicine supplying unit 3. The supplied medicine M is introduced into the packing paper 11 from the open edge 11a side of the packing paper 11 through the nozzle section 67a of the hopper 67. The heat sealing section 68 seals the packing paper 11 to confine the medicine M introduced into the packing paper 11. The printing unit 69 is disposed between the sheet supply unit 63 and the unfolding guide 65 on the movement path of the packaging paper 11. The printing unit 69 prints information such as the patient's name, drug name, and usage on the packaging paper 11.

[0024] Packing paper 11 passing through packaging unit 4 may have perforations (104 in FIG. 8) formed in the sealed portion of packaging paper 11. The perforations can be formed by a conventional method, for example, as shown in JP 2004-308973 A, by clamping the packaging paper 11 between a cutter having a plurality of blades arranged at a predetermined interval and a backing plate made of silicone rubber or the like, perforations can be formed according to the intervals between the plurality of blades. For this reason, the packaging unit 4 may be provided with a cutter and a backing plate (not shown).

[0025] The medicine packaging device 1 is configured to be able to determine the remaining amount of packaging paper 11 in the medicine packaging roll 10. Fig. 6 is a cross-sectional view of core tube 12 of medicine packaging roll 10 attached to roll support part 15. Figs. 7A and 7B are perspective views showing the internal configuration of roll support part 15.

[0026] The core tube 12 is composed of an inner tube portion 121a and an outer tube portion 121b. A core tube IC tag (e.g., RFID: Radio Frequency Identification) 122 serving as a recording medium is disposed in the gap between the inner tube portion 121a and the outer tube portion 121b of the core tube 12. A ring-shaped ferromagnetic body (e.g., a ring-shaped iron member) 121c is provided at the inner end of the core tube 12. A ring-shaped lid portion 121d that closes the gap is provided at the front end of the core tube 12.

[0027] The roll support 15 has a fixed shaft 151 and a rotating shaft 152 that rotates around the fixed shaft 151. The roll support 15 is attached to the medicine packaging device 1 by attaching and tightening a nut 151a to the base end side of the fixed shaft 151. The medicine packaging roll 10 is attached to the medicine packaging device 1 by fitting the core tube 12 into the rotating shaft 152. For example, four magnets 152a are provided at equal intervals on the surface of the flange of the rotating shaft 152. When the medicine packaging roll 10 is attached to the roll support 15, the ferromagnetic body 121c is attracted to the magnet 152a and the core tube 12 is fixed. In this state, when the medicine packaging roll 10 rotates, the rotating shaft 152 rotates.

[0028] A gear portion (not shown) is provided on the base end side of the rotating shaft portion 152. A small gear of a motor (not shown) provided to apply a braking effect to the rotating shaft portion 152 is meshed with this gear portion. The motor is an AC motor, and generates an appropriate braking force by applying an appropriate DC voltage. In adjusting the paper tension of the medicine packaging roll 10 by this braking force, for example, as shown in Japanese Patent No. 2909450, a sensor consisting of a magnet and a Hall element is used to find the remaining paper diameter of the medicine packaging roll 10, and the DC voltage can be adjusted in stages according to this remaining paper diameter.

[0029] The fixed shaft portion 151 has a hollow structure. A wiring 159 can be passed through this hollow interior. A board support member 153 is fixed to the tip side of the fixed shaft portion 151. A circuit board 154 is supported on this board support member 153. A photosensor 154a, which is composed of, for example, a light emitting portion and a light receiving portion, is provided on the back side of the circuit board 154 (the side opposite to the board support member 153 side of the circuit board 154). Meanwhile, 24 protrusions 152b (shown by two-dot chain lines in FIG. 7B) are formed in a circumferential shape on the end surface of the rotating shaft portion 152 (omitted in FIG. 7B) facing the circuit board 154. When the rotating shaft portion 152 rotates, the protrusions 152b pass between the light emitting portion and the light receiving portion of the photosensor 154a in sequence. As a result, the rotation state of the rotating shaft portion 152 is detected by the photosensor 154a. The controller 18 detects the output of the photosensor 154a via the wiring 159 to generate a count value, and is able to know the rotation state of the rotating shaft portion 152. The photosensor 154a outputs the count value as rotation amount information indicating the amount of rotation of the rotating shaft portion 152, but is not limited to such a count value output.

[0030] An antenna 155 is provided in a spiral shape on the front surface side of the circuit board 154 (the side of the circuit board 154 facing the board support member 153) so as to intersect with the axial direction of the rotating shaft portion 152 (the axial direction of the fixed shaft portion 151). This antenna 155 is also connected to a wiring 159. The board support member 153 and the circuit board 154 are covered by a cap portion 152c provided on the tip side of the rotating shaft portion 152. It is desirable that the antenna surface of the core tube IC tag 122 is disposed so as not to intersect with the extension of the surface on which the antenna 155 is formed.

[0031] In the medicine packaging device 1, the remaining amount of packaging paper 11 in the medicine packaging roll 10 is determined by a controller 18 included in the medicine packaging device 1. FIG. 8 is an explanatory diagram showing the configuration of a paper remaining amount determining unit in controller 18 of medicine packing device 1. As shown in FIG. The wireless reader / writer (information reading unit) 156 is controlled by the controller 18. The wireless reader / writer 156 is configured to read information from the core tube IC tag 122 and write information to the core tube IC tag 122. Note that, in order to prevent unauthorized rewriting of the information, the information may be encrypted or compressed before being written to the core tube IC tag 122.

[0032] Information generating unit 167a of paper remaining amount determining unit 167 generates a count value (corresponding to rotation amount information at the reference paper remaining amount time point) based on the output of photosensor 154a when a certain length (e.g., 80 mm, which is one packet) of packaging paper 11 of medicine packaging roll 10 has been sent out at a reference time point, as information to be written to core tube IC tag 122. Whether packaging paper 11 has been sent out by the certain length can be determined by controller 18 based on the amount of rotation of a roller for feeding packaging paper 11 provided in packaging unit 4, etc.

[0033] Furthermore, information generating unit 167a generates a count value (corresponding to multiple rotation amount information at the time of the current remaining amount of paper) based on the output of photosensor 154a for multiple times each time the packet paper 11 of medicine packaging roll 10 is sent out at the time the packet paper is used after the reference time point. Furthermore, information generating unit 167a generates the number of packets elapsed since the reference time point as the amount of paper used from the reference time point to the time the packet paper is used. It is also possible to adopt a configuration in which the current count value is set to one, which is the latest current remaining amount of paper, instead of a plurality of counts. Moreover, the rotation amount information is not limited to the count value. Furthermore, the amount of paper used from the reference time point to the time when the packaging paper is used is not limited to the number of packages that have passed, but the length of paper used, etc. can also be used. The count value generated by the information generating unit 167 a may be stored in the memory 165 . The controller 18 uses these count values ​​to calculate the remaining amount of the packaging paper 11. The remaining amount of packaging paper 11 can be calculated, for example, using the method described in Patent Publication No. 2020-28733.

[0034] FIG. 9A is an explanatory diagram showing a state in which medicines are packaged in packet paper 11, and FIG. 9B is a partially enlarged view of FIG. 9A. The medicine packaging device 1 can supply a medicine packaging band 100 in which a plurality of packaging bags 101, each of which packs a single dose of medicine M, are connected in a strip-like shape, as shown in FIG. 9A. In the medicine packet 100, a vertical seal 103 is formed that closes the elongated packet paper 11 folded in half along the longitudinal direction in the short direction, and a horizontal seal 102 is formed that closes the open edge 11a of the folded packet paper 11. This forms a plurality of packet bags 101, each containing a single dose of the medicine M. The vertical seal 103 of the medicine sachet 100 is formed with perforations 104 to facilitate separation of the sachets 101 from each other.

[0035] The packaging paper 11 is a biodegradable packaging paper having a configuration described in detail later. The packaging paper 11 is harder than conventional packaging paper using cellopoly paper, and tends to be easily torn apart when folded along the perforations. Therefore, if perforations are formed with the same dimensions as conventional sachet paper made of cellopoly paper, the sachets 101 may be separated from each other just by folding along the perforations. In other words, the sachets 101 may be separated from each other at a time unintended by the patient, medical staff, etc. To prevent such problems from occurring, it is preferable that the dimensions of perforations 104 are coarser than the dimensions of perforations formed in conventional packaging paper made of cellopoly paper. The dimensions of perforation 104 are, for example, such that length L1 of cut portion 104a shown in FIG. 9B is 1.5 mm or more and 2.25 mm or less, and length L2 of uncut portion 104b is 0.75 mm or more and 1.5 mm or less, and it is preferable that L1>L2.

[0036] Next, the packaging paper 11 according to this embodiment will be described in detail. Returning to Figures 2A to 2C, packaging paper 11 is a long, narrow, strip-shaped sheet. Packaging paper 11 is a laminate having first resin layer 111 and second resin layer 112. As already explained, packaging paper 11 is folded in half in advance along the longitudinal direction, and wrapped around the outer periphery of core tube 12 with one edge along the longitudinal direction being open edge 11a and the other edge being fold 11b. At this time, packaging paper 11 is folded in half so that first resin layers 111 face each other.

[0037] The rate of biodegradable components contained in the entire packaging paper 11 is 90% by mass or more. Here, the biodegradable component refers to a component that can be decomposed by microorganisms and turned into compost. Therefore, the packet paper 11 is an environmentally friendly packet paper in which 90% or more by mass of the components contained in the packet paper are decomposed by composting. The proportion of biodegradable components contained in the entire packaging paper 11 is preferably 95% by mass or more, more preferably 97% by mass or more, even more preferably 98% by mass or more, and particularly preferably 99% by mass or more.

[0038] From the viewpoint of making the packaging paper 11 more suitable for composting, the total mass of the biodegradable resin contained in the first resin layer 111 and the cellophane contained in the second resin layer 112 is preferably 90% or more of the total mass of the packaging paper 11. This total mass is more preferably 95% or more, even more preferably 97% or more, particularly preferably 98% or more, and most preferably 99% or more.

[0039] It is preferable that the packaging paper 11 is compostable and exhibits a high degree of disintegration when evaluated by a disintegration test conforming to ISO 16929 (2021). It is more preferable that the validity of the disintegration test is confirmed in the evaluation of the packaging paper 11 by this disintegration test, and the degree of disintegration of the test material after 12 weeks is 90% or more. In this evaluation, the test material is a sachet 101 (no medicine packed therein) that is heat sealed (vertical and horizontal seals) on the sachet paper 11. The length and width of the sachet as the test material are each 10 cm or less (for example, about 8 cm in length and about 7 cm in width).

[0040] The first resin layer 111 is made of a resin composition containing at least two kinds of biodegradable resins. Since first resin layer 111 contains two or more types of biodegradable resins, the laminate has flexibility and transparency suitable for use as a packaging paper. Hereinafter, the resin composition constituting the first resin layer 111 will also be referred to as a first resin composition.

[0041] The biodegradable resin may be any resin having biodegradability, and examples thereof include aliphatic polyester resins, aliphatic / aromatic polyester resins, polyamide resins such as 4-nylon, polyamino acid resins such as polyaspartic acid, polyether resins such as polyethylene glycol and polypropylene glycol, polysaccharides such as cellulose and pullulan, and polyvinyl alcohol resins.

[0042] The first resin composition preferably contains, as the biodegradable resin, a polyester copolymer using a diol and a dicarboxylic acid as monomer components, and a polylactic acid resin. When these resins are contained as the biodegradable resin, it is suitable for ensuring flexibility and transparency suitable for packaging paper.

[0043] The polyester copolymer contains a diol and a dicarboxylic acid as monomer components. The diol includes, for example, a compound represented by the following formula (1). H.O.R. 1 -OH···(1) (In the formula, R 1 is a divalent hydrocarbon group which may contain an oxygen atom in the chain. Above R 1 is, for example, an aliphatic hydrocarbon group or an alicyclic hydrocarbon group. These hydrocarbon groups may be linear or may have a branched chain.

[0044] Specific examples of the diol include aliphatic diols such as ethylene glycol, 1,3-propanediol, 1,2-propanediol, 1,4-butanediol, 1,5-pentanediol, and 1,6-hexanediol, 1,4-cyclohexanediol, 1,4-cyclohexanedimethanol, diethylene glycol, dipropylene glycol, and triethylene glycol. Among these, aliphatic diols are preferred, and 1,4-butanediol is more preferred.

[0045] The dicarboxylic acid may, for example, be a compound represented by the following formula (2). HOOC-(R 2 )n-COOH···(2) (In the formula, R 2 is a divalent hydrocarbon group, and n represents 0 or 1. If n is 1, then R 2is, for example, an aliphatic hydrocarbon group, an alicyclic hydrocarbon group, or an aromatic hydrocarbon group. These hydrocarbon groups may be linear or may have a branched chain.

[0046] Specific examples of the dicarboxylic acid include aliphatic dicarboxylic acids or alicyclic dicarboxylic acids such as oxalic acid, malonic acid, succinic acid, glutaric acid, adipic acid, azelaic acid, sebacic acid, heptanedioic acid, octanedioic acid, nonanedioic acid, decanedioic acid, undecanedioic acid, dodecanedioic acid, tridecanedioic acid, tetradecanedioic acid, pentadecanedioic acid, hexadecanedioic acid, octadecanedioic acid, eicosane diacid, maleic acid, fumaric acid, 1,6-cyclohexanedicarboxylic acid, and dimer acid, and aromatic dicarboxylic acids such as isophthalic acid, terephthalic acid, and 2,6-naphthalenedicarboxylic acid. Among these, aliphatic dicarboxylic acids are preferred, and succinic acid is more preferred. As the dicarboxylic acid, succinic acid derived from plant raw materials is particularly preferred from the viewpoint of being more environmentally friendly.

[0047] The polyester copolymer may contain, as a monomer component, other monomer components in addition to the diol and the dicarboxylic acid. Examples of the other monomer components include oxycarboxylic acids. The oxycarboxylic acid may, for example, be a compound represented by the following formula (3). H.O.R. 3 -COOH···(3) (In the formula, R 3 is a divalent hydrocarbon group. Above R 3 is, for example, an aliphatic hydrocarbon group, an alicyclic hydrocarbon group, or an aromatic hydrocarbon group. These hydrocarbon groups may be linear or may have a branched chain.

[0048] Specific examples of the oxycarboxylic acid include lactic acid, glycolic acid, 2-hydroxy-n-butyric acid, 2-hydroxycaproic acid, 2-hydroxy-3,3-dimethylbutyric acid, 2-hydroxy-3-methylbutyric acid, 2-hydroxyisocaproic acid, 4-hydroxycyclohexanecarboxylic acid, and 4-hydroxymethylcyclohexanecarboxylic acid.

[0049] When the polyester copolymer contains an oxycarboxylic acid as a monomer component, the content of the oxycarboxylic acid is, for example, 0.1 to 20 parts by mass with respect to 100 parts by mass of the dicarboxylic acid.

[0050] The polyester copolymer may contain, as the other monomer component, a polyfunctional monomer component having three or more functional groups, such as a trifunctional or higher polyhydric alcohol, a trifunctional or higher polycarboxylic acid, or a trifunctional or higher polyoxycarboxylic acid.

[0051] As the polyester copolymer, polybutylene succinate (PBS) containing 1,4-butanediol and succinic acid as monomer components is preferred. When used in combination with a polylactic acid resin, which will be described later, it is suitable for obtaining a packaging paper having good transparency and flexibility.

[0052] From the viewpoint of achieving good moldability when producing the first resin layer 111, the MFR of the polyester copolymer is preferably 3 to 10 g / 10 min.

[0053] Examples of the polylactic acid resin include poly(D-lactic acid), poly(L-lactic acid), a copolymer of D-lactic acid and L-lactic acid [poly(DL-lactic acid)], and mixtures thereof. The mixture of polylactic acids may form a stereocomplex.

[0054] The polylactic acid resin may be a copolymer of lactic acid and another monomer component other than lactic acid, such as a glycol compound or a hydroxycarboxylic acid. Examples of the glycol compounds include ethylene glycol, propylene glycol, butanediol, heptanediol, hexanediol, octanediol, nonanediol, decanediol, 1,4-cyclohexanedimethanol, neopentyl glycol, glycerin, pentaerythritol, bisphenol A, polyethylene glycol, polypropylene glycol, and polytetramethylene glycol. Examples of the hydroxycarboxylic acid include dicarboxylic acids such as oxalic acid, adipic acid, sebacic acid, azelaic acid, dodecanedioic acid, malonic acid, glutaric acid, cyclohexanedicarboxylic acid, terephthalic acid, isophthalic acid, phthalic acid, naphthalenedicarboxylic acid, bis(p-carboxyphenyl)methane, anthracenedicarboxylic acid, 4,4'-diphenyletherdicarboxylic acid, 5-sodiumsulfoisophthalic acid, and 5-tetrabutylphosphonium isophthalic acid, as well as glycolic acid, hydroxypropionic acid, hydroxybutyric acid, hydroxyvaleric acid, hydroxycaproic acid, and hydroxybenzoic acid.

[0055] The polylactic acid resins exemplified above may be used alone or in combination of two or more kinds. Of the polylactic acid-based resins, polylactic acid-based resins made from plants such as corn are preferred because they are more environmentally friendly.

[0056] From the viewpoint of achieving good moldability when producing the first resin layer 111, the MFR of the polylactic acid resin is preferably 10 to 15 g / 10 min.

[0057] As the biodegradable resin, commercially available products can also be used. Commercially available products of the polyester copolymer include, for example, BioBPS and FZ91PM manufactured by Mitsubishi Chemical Corporation. Commercially available products of the polylactic acid resin include, for example, Terramac TE-2000C and Terramac TP-3000 manufactured by Unitika Ltd.

[0058] When the first resin composition contains the polyester-based copolymer and the polylactic acid-based resin, it is preferable that the content of the polyester-based copolymer is less than 50 mass% relative to the total amount of the polyester-based copolymer and the polylactic acid-based resin. Mixing the polyester copolymer and the polylactic acid resin in such a ratio is suitable for achieving a good balance between flexibility and transparency of the packaging paper 11. On the other hand, if the content of the polyester copolymer is 50% by mass or more, the wrapping paper may have poor transparency, and may also have poor moldability during production of the wrapping paper, which may lead to variations in layer thickness and reduced yield. The preferred lower limit of the content of the polyester copolymer is 20% by mass based on the total amount of the polyester copolymer and the polylactic acid resin.

[0059] When the first resin composition contains the polyester-based copolymer and the polylactic acid-based resin, the content of the polyester-based copolymer relative to the total amount of the polyester-based copolymer and the polylactic acid-based resin is more preferably 20% by mass or more and 45% by mass or less, from the viewpoint of achieving a better balance between the flexibility and transparency of the packaging paper 11.

[0060] In this case, the formability when producing the packaging paper by extrusion molding is also good, making it easier to ensure uniformity in the thickness of the produced packaging paper. On the other hand, if the content of the polyester copolymer is low (if the content of the polylactic acid resin is high), the flexibility is reduced and the wrapping paper may become hard and stiff to the touch. Also, if the content of the polyester copolymer is high (if the content of the polylactic acid resin is low), the transparency may decrease and the yield may decrease due to poor moldability. In particular, when the polyester copolymer is polybutylene succinate, the content ratio of the polyester copolymer to the polylactic acid resin is preferably within the above range.

[0061] The first resin composition may contain other components such as antioxidants, ultraviolet absorbers, antistatic agents, plasticizers, lubricants, etc. The amount of these other components added is not particularly limited as long as the properties required for the packaging paper are not impaired.

[0062] The thickness of first resin layer 111 is preferably 30 to 70 μm, and more preferably 40 to 50 μm. In this case, a packaging paper provided with first resin layer 111 is suitable for ensuring the strength, flexibility, and transparency required of a packaging paper.

[0063] The second resin layer 112 is made of moisture-proof cellophane. The moisture-proof cellophane is a film in which a moisture-proof layer is provided on one side (the side facing the first resin layer 111) of a base layer made of cellophane. Examples of materials for the moisture-proof layer include polyvinylidene chloride, copolymers containing vinylidene chloride as a main monomer component, polyvinyl chloride, copolymers containing vinyl chloride as a main monomer component, and the like. Here, the term "main monomer component" means that the proportion of the monomer component in the total monomer components exceeds 50% by mass. The moisture-proof layer may be made of a biodegradable resin. The moisture-proof layer may be formed on both sides of the base layer made of cellophane.

[0064] As the moisture-proof cellophane, commercially available products can also be used. Examples of commercially available moisture-proof cellophane include MOKZ3-Y manufactured by Futamura Chemical Co., Ltd. and Moisture-proof Cellophane NK manufactured by Innovia Corporation.

[0065] The second resin layer 112 has a thickness of, for example, 20 to 24 μm. The thickness of the moisture-proof layer is, for example, 1 to 2 μm per side. In the second resin layer 112, the thickness of the base layer (thickness of the cellophane) is preferably 19 to 20 μm.

[0066] Between the first resin layer 111 and the second resin layer 112, an adhesive layer (not shown) formed by using an anchor coating agent may be provided as necessary. When the adhesive layer is formed, the adhesion between the first resin layer 111 and the second resin layer 112 becomes stronger.

[0067] As the anchor coating agent, a conventionally known anchor coating agent can be used in consideration of the materials of the first resin layer 111 and the second resin layer 112. Examples of the anchor coating agent include a urethane-based anchor coating agent, an imine-based anchor coating agent, a butadiene-based anchor coating agent, a titanate-based anchor coating agent, etc. Among these, a urethane-based anchor coating agent is preferred.

[0068] As the anchor coating agent, commercially available products can also be used. Commercially available anchor coating agents include, for example, Titabond T-120A / T-300H manufactured by Nippon Soda Co., Ltd., and Resitex U-2025 manufactured by Resitex Corporation. Of these, Resitex U-2025 is preferred because adhesive strength can be easily achieved with a small amount.

[0069] Next, the method for producing the above-mentioned packaging paper will be described in order of steps. The above-mentioned packaging paper can be produced, for example, by an extrusion lamination method in which a first resin layer extruded using a T-die is laminated on a second resin layer. Fig. 10 is a diagram for explaining an example of a method for producing a packaging paper according to the present embodiment, which mainly shows the lamination portion of an extrusion lamination device. Hereinafter, the method for producing the packet paper will be described taking as an example a case in which the biodegradable resin contained in the first resin composition is a polyester-based copolymer and a polylactic acid-based resin.

[0070] (1) As raw materials, pellets of a polyester copolymer, pellets of a polylactic acid resin, and additives such as an antioxidant, which are added as necessary, are prepared, and a mixture is prepared by mixing these raw materials. Here, the raw materials may be mixed using, for example, a conventionally known mixer. It is also possible to melt-knead the polyester copolymer and the polylactic acid resin in advance to prepare pellets containing both, and use these as raw materials for the polyester copolymer and the polylactic acid resin.

[0071] (2) The mixture of raw materials prepared in (1) above is fed into hoppers 52A and 52B of extrusion laminator 50 to produce packaging paper 11. The extrusion lamination apparatus 50 includes a first extruder 51A having a hopper 52A, a second extruder 51B having a hopper 52B, a T-die 56, and various rolls including a cooling roll 58 and a pressing roll 59. The first extruder 51A and the second extruder 51B are both single-screw extruders.

[0072] The mixture of raw materials fed from the hoppers 52A and 52B is melt-kneaded in the first extruder 51A and the second extruder 51B, respectively, and then joined in the feed section 54 and supplied to the T-die 56. Thereafter, the mixture is extruded from the discharge port of the T-die as a sheet-shaped first resin layer precursor 211. This sheet-shaped first resin layer precursor 211 is laminated on moisture-proof cellophane 212.

[0073] Before being conveyed to the pressing roll 59 (upstream of the pressing roll 59), the moisture-proof cellophane 212 may be coated with an anchor coating agent on one side (the surface to be bonded to the first resin layer). When applying the anchor coating agent, the anchor coating agent may be applied after, for example, being diluted with a solvent. Specifically, for example, when the anchor coating agent is Resitex U-2025, the anchor coating agent may be diluted with methanol and applied. In this case, the mass ratio of the anchor coating agent to methanol is preferably anchor coating agent:methanol=1 to 5:10. This is because it is suitable for ensuring adhesion between the first resin layer and the second resin layer while applying the anchor coating agent thinly and with a uniform thickness. The diluted solution of Resitex U-2025 is preferably applied to the moisture-proof cellophane 212 and then dried by heating at 80°C or higher.

[0074] The first resin layer precursor 211 is laminated onto one side of moisture-proof cellophane 212 (the side to which an anchor coating agent is applied, if an anchor coating agent is applied), and in this state passes between cooling roll 58 and pressing roll 59, whereby it is cooled and pressed onto the moisture-proof cellophane 212 to become the first resin layer 111. By going through these steps, it is possible to manufacture packaging paper 11 in which first resin layer 111 is laminated on one side of second resin layer 112 made of moisture-proof cellophane. Packaging paper 11 is wound into a roll for storage and transportation.

[0075] In the manufacturing process of such packaging paper, the manufacturing conditions of the extrusion laminator 50 may be, for example, the following conditions. The outlet temperatures of the extruders 51A and 51B can be, for example, 210 to 270° C. The first extruder 51A and the second extruder 51B usually adopt the same conditions, but may adopt different conditions. The outlet temperature of the T-die 56 can be set to, for example, 200 to 230°C. The distance (air gap) D from the exit of the T-die 56 to the cooling roll can be set to, for example, 100 to 150 mm. The processing speed of the packaging paper 11 can be, for example, 40 to 120 m / min.

[0076] The medicine packaging roll of this embodiment can be manufactured by cutting the packaging paper 11 manufactured by the method described above to a predetermined width dimension (e.g., 140 mm), then folding it in half along the longitudinal direction, and wrapping it around a core tube in this state. When manufacturing the medicine packaging roll, an anti-blocking agent may be applied to one side of the folded packaging paper, which prevents the moisture-proof cellophane from sticking together. The above-mentioned antiblocking agent is preferably one having biodegradability, and particularly preferably an antiblocking agent derived from a plant raw material.

[0077] (Other embodiments) The medicine packaging roll according to the embodiment of the present invention is not limited to a so-called double-type medicine packaging roll in which a strip-shaped packaging paper is folded in half along the longitudinal direction and wound around a core tube. The medicine packaging roll according to the embodiment of the present invention may be a so-called single-type medicine packaging roll in which a strip-shaped packaging paper having a predetermined width is wound around a core tube as it is without being folded in half. In this case, the roll is attached to a medicine packaging device that is compatible with a single-type medicine packaging roll.

[0078] The packaging paper according to the embodiment of the present invention may be provided with a strip-shaped white layer extending in the longitudinal direction on the outer surface of the second resin layer (the surface opposite to the first resin layer). In the case of a packaging paper provided with the above-mentioned white layer, by printing information such as the patient's name, drug name, and usage on this white layer, the visibility of the printed information is improved.

[0079] The white layer can be formed, for example, by printing a white ink by gravure printing, flexographic printing or the like. Moreover, in the packaging paper 11, a colored layer of another color may be formed instead of the white layer.

[0080] Although the above-mentioned extrusion lamination device is equipped with two extruders, the packaging paper according to the embodiment of the present invention may be produced using an extrusion lamination device equipped with only one extruder. EXAMPLES

[0081] The embodiments of the present invention will be described in more detail below with reference to examples, but the present invention is not limited to the following examples. In Examples 1 to 3, packaging papers (rolls for packaging medicines) were produced and evaluated. As Comparative Example 1, a commercially available medicine packaging roll made of cellopoly paper (Yuyama Manufacturing Co., Ltd., 70W) was prepared and evaluated in the same manner as in Examples 1 and 2. In Example 4, packaging paper (rolls for packaging medicines) was produced and the quality was confirmed. The packaging papers (medicine packaging rolls) of Examples 1 to 4 were designed so that the proportion of biodegradable components contained in the entire packaging paper was 90% by mass or more.

[0082] [raw materials] (A) First resin layer Polybutylene succinate (Mitsubishi Chemical Corporation, BioPBS FZ91PM) Polylactic acid resin (Terramac TE-2000C, manufactured by Unitika) (B) Second resin layer Moisture-proof cellophane (Futamura Chemical Co., Ltd., MOKZ3-Y #300) (C) Anchor coating agent - Urethane anchor coating agent (Titabond T-120A / T-300H, manufactured by Nippon Soda Co., Ltd.) - Urethane anchor coating agent (Resitex U-2025, manufactured by Resitex) (D) Other White ink (DIC Graphics, Sias HR White) ·Anti-blocking powder (Nikka AS-100S)

[0083] [Manufacturing equipment] An extrusion lamination device 50 (see FIG. 10) having two single-screw extruders 51A and 51B and an Autoflex T-die manufactured by Sumitomo Heavy Industries Modern Co., Ltd. as a T-die 56 was used.

[0084] [Manufacturing conditions] The first extruder 51A and the second extruder 51B were driven under the same conditions. The outlet temperature of each of the first extruder 51A and the second extruder 51B was set to 240°C. The outlet temperature of the T-die 56 was set to 215 to 220°C. The distance (air gap) D from the exit of the T-die 56 to the cooling roll 58 was set to 120 mm. The processing speed was 60 m / min.

[0085] Example 1 A packaging paper having a first resin layer of BioPBS FZ91PM:Terramac TE-2000C=20:80 (by mass) was produced. 20 parts by mass of BioPBS FZ91PM pellets and 80 parts by mass of Terramac TE-2000C pellets were mixed to prepare a raw material mixture.

[0086] The mixture of raw materials was fed into the first extruder 51A and the second extruder 51B via hoppers 52A and 52B, and the extrusion laminating device 50 was operated under the above-mentioned manufacturing conditions to produce a packaging paper in which a first resin layer containing polybutylene succinate and polylactic acid resin was laminated on one side of moisture-proof cellophane coated with an anchor coating agent (Titabond T-120A / T-300H).

[0087] The packaging paper was then cut to a width of 140 mm and folded in half along the longitudinal direction. A white print layer was then drawn on one side of the folded packaging paper in a width of 55 mm along the longitudinal direction, and anti-blocking powder was applied to the other side of the packaging paper. The packaging paper was then wound around a core tube in a roll shape with the anti-blocking powder applied side facing inward to complete a pharmaceutical packaging roll. Here, the first resin layer had a thickness of 40 μm, and the second resin layer had a thickness of 20 μm.

[0088] Example 2 A medicine packaging roll was produced in the same manner as in Example 1, except that the blending ratio of BioPBS FZ91PM and Terramac TE-2000C was changed to 30:70 (by mass).

[0089] Example 3 A medicine packaging roll was produced in the same manner as in Example 1, except that the blending ratio of BioPBS FZ91PM and Terramac TE-2000C was changed to 40:60 (by mass).

[0090] [evaluation] (1) Evaluation of biodegradability, (2) moisture permeability test, (3) tensile strength measurement, and (4) inspection evaluation were carried out. The evaluation of (1) was carried out using the packaging paper of Example 3. The evaluations of (2) and (3) were carried out using the packaging papers of Examples 1 to 3 and Comparative Example 1. The evaluation of (4) was carried out using the packaging papers of Examples 1 and 2 and Comparative Example 1.

[0091] (1) Evaluation of biodegradability The packaging paper of Example 3 was subjected to a disintegration test in accordance with ISO 16929. For this test, several individual packets, each approximately 7 cm wide and 8 cm long, with the three sides other than the folds heat sealed, were prepared and used as the test materials. As a result, the composting process progressed and most of the packaging paper had disintegrated.

[0092] (2) Moisture permeability test The test was carried out in accordance with JAPAN TAPPI No. 7 Paper and Paperboard - Moisture Permeability Test Method A. The results are shown in Table 1. The test was performed three times, and the average value was used as the measurement result.

[0093] (3) Tensile strength measurement Tensile strength measurements were performed in accordance with "JIS P 8113 Paper and paperboard-Test methods for tensile properties," "JIS P 8110 Test paper sampling method," and "JIS P 8111 Paper, paperboard and pulp-Standard conditions for conditioning and testing." The results are shown in Table 1. The pretreatment conditions for the test pieces were humidity conditioning for 24 hours in a temperature and humidity controlled room at a temperature of 23°C and a humidity of 50%. The test machine used was a load cell type tensile tester RTG-1210. Furthermore, · Test piece orientation: Vertical and horizontal measurement Specimen width: 15mm - Length of test piece: 180mm length, 40mm width, Pulling speed: 100mm / min Number of tests: 10 It was decided. The measurements were taken with the test piece open and folded in half, and the average value was recorded as the measurement result.

[0094] [Table 1]

[0095] As shown in the results in Table 1, the packaging papers of Examples 1 to 3 had lower moisture permeability compared to conventional packaging paper (Comparative Example 1). Since moisture is a big problem for packaging papers for medicines, the packaging papers of Examples 1 to 3 are suitable packaging papers. Furthermore, the packaging papers of Examples 1 to 3 had a higher tensile strength than conventional packaging paper (Comparative Example 1). As already explained, the band-shaped packaging paper unwound from the medicine packaging roll attached to the medicine packaging device is fed to the printing section, unfolding guide, heat seal section, etc. via various rollers in the device, and the medicine is packaged for one dose. At this time, various tensions are applied to the packaging paper within the medicine packaging device, but the packaging papers of Examples 1 to 3 have a high tensile strength and are therefore less likely to break, and stable packaging operation can be expected even when various tensions are applied.

[0096] (4) Inspection and evaluation The following evaluation tests were conducted using a single-dose tablet inspection support device (TabSight-S, manufactured by Yuyama Manufacturing Co., Ltd.). (1) Prepare a white dummy tablet, a yellow dummy tablet, and a blue dummy tablet, and take a picture of each bare tablet (master image) using TabSight-S. (2) Using the packaging paper (medication packaging rolls) of Examples 1 and 2 and Comparative Example 1, the tablets are packaged in multiple packages of three tablets each, and the images are inspected and compared with the master image using TabSight-S. (3) After all the shooting has been completed, the RGB values ​​relating to the red (R), green (G), and blue (B) information, and the HSV values ​​relating to the hue, saturation, and value (Value) are obtained from the information recorded in the TabSight-S. The RGB and HSV values ​​obtained from the packaged dummy medicine are then compared with those of the master image to obtain the difference between them, and if the difference between them for one or more of the R, G, B, H, S, and V values ​​is greater than a predetermined threshold, it is determined that the match is incorrect.On the other hand, if the difference between them for all of the R, G, B, H, S, and V values ​​is equal to or less than the predetermined threshold, it is determined that the match is correct.

[0097] As a result, for the white dummy tablets and the yellow dummy tablets, proper matching was possible for all the dummy tablets in the packaging papers of Examples 1 and 2, as well as the packaging paper of Comparative Example 1. Furthermore, for the blue dummy tablets, matching failures occurred in both the packaging paper of Examples 1 and 2 and the packaging paper of Comparative Example 1. Furthermore, the incidence rate of matching failures in the packaging paper of Examples 1 and 2 (hereinafter, the matching failure rate) was higher than the matching failure rate of the packaging paper of Comparative Example 1, but the difference between the matching failure rates of the packaging paper of Examples 1 and 2 and the matching failure rate of the packaging paper of Comparative Example 1 was small. From this, it was found that the packaging papers of Examples 1 and 2 also had sufficient transparency and could be inspected using a tablet inspection support device, just like conventional packaging papers.

[0098] Example 4 A medicine packaging roll was produced in the same manner as in Example 2, except that the type of anchor coating agent and the application method were changed. In this example, the anchor coating agent was changed from Titabond T-120A / T-300H to Resitex U-2025. Resitex U-2025 was diluted with methanol at a mass ratio (Resitex U-2025:methanol = 2:10) and applied. After application, the anchor coating agent was dried at 80°C or higher and lower than 100°C.

[0099] The packaging paper (medicine packaging roll) manufactured in Example 4 had the uniform thickness and strength required for packaging paper, and could be used well in commercially available medicine packaging devices. The packaging paper of this example is expected to show a higher degree of disintegration than that of Example 1 when subjected to a disintegration test in accordance with ISO 16929. [Explanation of symbols]

[0100] 1. Drug packaging device 2 Tablet supply unit 3 Powdered medicine supply unit 4 Packaging Unit 5. Drug Collection Department 6. Housing 8 Cover 9. Control Panel 10. Drug packaging roll 11 wrapping paper 11a Open Edge 11b Fold 12 core tube 13 Through hole 15 Roll support part 18 Controller 21 Tablet storage box 25 Blockade Cover 26 Protective cover 31 V-cup 32 Partition 50 Extrusion Lamination Equipment 51A (1st) Extruder 51B (2nd) Extruder 52A, 50B Hopper 54 Feed section 56 T-die 58 Cooling roll 59 Pressing roll 63 Sheet supply unit 65 Deployment Guide 67 Hopper 67a Nozzle part 68 Heat seal section 69 Printing Department 70 Heat Roller 71 Guide roller 100 Drug Packets 101 sachets 102 Horizontal seal 103 Vertical Seal 104 Perforation 104a Cutting section 104b Uncut section 111 1st resin layer 112 Second resin layer 121a Inner pipe section 121b Outer pipe section 121c ferromagnetic material 121d Lid 122 Core tube IC tag 151 Fixed shaft part 151a Nut 152 Rotating shaft 152a Magnet 152b Protrusion 152c Cap 153 Substrate support member 154 Circuit Board 154a Photo sensor 155 Antenna 156 Wireless reader / writer (information reading unit) 159 Wiring 165 Memory 167 Paper remaining amount determination unit 167a Information generation section 211 First resin layer precursor 212 Moisture-proof cellophane M Drug

Claims

1. A first resin layer made of a resin composition containing at least two types of biodegradable resins; A second resin layer made of moisture-proof cellophane; Equipped with The first resin layer contains, as the biodegradable resin, a polyester-based copolymer using a diol and a dicarboxylic acid as monomer components, and a polylactic acid-based resin, The polyester copolymer is polybutylene succinate, The content of the polyester-based copolymer is 20% by mass or more and 45% by mass or less based on the total amount of the polyester-based copolymer and the polylactic acid-based resin, A packaging paper in which the proportion of biodegradable components contained in the entire packaging paper is 90% by mass or more.

2. The packaging paper according to claim 1 , wherein the content of the polyester-based copolymer is 20% by mass or more and 40% by mass or less based on the total amount of the polyester-based copolymer and the polylactic acid-based resin.

3. A medicine packaging roll comprising a strip-shaped packaging paper and a core tube, the packaging paper being wound around the core tube in a roll shape, the packaging paper being the packaging paper described in claim 1 or 2.

4. The medicine packaging roll according to claim 3 , wherein the strip-shaped packaging paper is folded in half along the longitudinal direction and wrapped around the core tube.

Images